Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve block may fix COVID smell problems, study says

NCT ID NCT06253806

Symptom relief Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a stellate ganglion block (an injection near nerves in the neck) can improve distorted sense of smell (parosmia) caused by COVID-19. 48 adults with long-term smell issues after COVID took part. Half received the nerve block, half got a placebo (saline). The goal was to see if the treatment improves smell-related quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

48 people

The number who actually took part.

Started

Oct 2023

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults age 18 to 70 2. Diagnosis of COVID at least 6 months prior to study enrollment with self-reported parosmia 3. Ability to read, write, and understand English 4. Score of at least 40 on DiSODOR during screening and at least 25 during Visit 1 Exclusion Criteria: 1. History of smell loss or change prior to COVID-19 infection 2. History of conditions known to impact olfactory dysfunction 1. Chronic rhinosinusitis 2. History of prior sinonasal or skull base surgery 3. Neurodegenerative disorders (Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Lewy body dementia, frontotemporal dementia) 3. Currently using concomitant therapies specifically for the treatment of olfactory dysfunction 4. Inability to tolerate a needle injection into the neck 5. History of coexisting conditions that make SGB contraindicated: 1. Unilateral vocal cord paralysis 2. Severe COPD (FEV1 between 30-50% of predicted) 3. Recent myocardial infarction within the last year 4. Glaucoma 5. Cardiac conduction block of any degree 6. Currently taking blood thinners or antiplatelet agents, including aspirin \>81mg. 7. Allergy to local anesthetic 8. Inability to extend the neck for any reason (e.g., severe arthritis) 9. History of prior stellate ganglion block

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19-induced parosmia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anosmia Coronavinae infectious disease Coronaviridae Infections COVID-19 Infections long COVID-19 lung disorder nervous system disorder Neurologic Manifestations Nidovirales infectious disease pneumonia respiratory system disorder respiratory tract infectious disorder RNA Virus Infections Sensation Disorders viral infectious disease viral pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19-induced parosmia

Contacts and locations

Locations

  • Nyssa Fox Farrell

    St Louis, Missouri, 63122, United States